Deferred Tax Assets, Valuation Allowance of Viridian Therapeutics, Inc.\DE from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Viridian Therapeutics, Inc.\DE quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • Viridian Therapeutics, Inc.\DE Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $316,823,000, a 52% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Viridian Therapeutics, Inc.\DE Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $316,823,000 +$108,312,000 +52% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $208,511,000 +$52,777,000 +34% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $155,734,000 +$69,132,000 +80% 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q4 2022 $86,602,000 +$33,172,000 +62% 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q4 2021 $53,430,000 +$24,357,000 +84% 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q4 2020 $29,073,000 -$17,167,000 -37% 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q4 2019 $46,240,000 +$13,104,000 +40% 31 Dec 2019 10-K 26 Mar 2021 2020 FY
Q4 2018 $33,136,000 +$10,627,000 +47% 31 Dec 2018 10-K 13 Mar 2020 2019 FY
Q4 2017 $22,509,000 -$3,833,000 -15% 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q4 2016 $26,342,000 +$21,646,000 +461% 31 Dec 2016 10-K 15 Mar 2018 2017 FY
Q4 2015 $4,696,000 +$3,500,000 +293% 31 Dec 2015 10-K 24 Mar 2017 2016 FY
Q4 2014 $1,196,000 31 Dec 2014 10-K 21 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.